Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan E Shaw

Showing results (381-390 of 407) with videos related to

Pageof 41
Sort By:
Journal of Lipid Research|April 11, 2025
Statin effects on the lipidome: Predicting statin usage and implications for cardiovascular risk predictionChangyu Yi, Kevin Huynh, Yvette Schooneveldt, et al.
BMJ Open Diabetes Research & Care|January 8, 2020
Comparing different definitions of prediabetes with subsequent risk of diabetes: an individual participant data meta-analysis involving 76 513 individuals and 8208 cases of incident diabetesCrystal Man Ying Lee, Stephen Colagiuri, Mark Woodward, et al.
Cardiovascular Diabetology|November 26, 2020
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysisGilles R Dagenais, Lars Rydén, Lawrence A Leiter, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2022
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND TrialTali Cukierman-Yaffe, Hertzel C Gerstein, Jan Basile, et al.
The Lancet. Diabetes & Endocrinology|March 31, 2015
A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveysKaveh Hajifathalian, Peter Ueda, Yuan Lu, et al.
The Lancet. Neurology|June 21, 2020
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialTali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, et al.
The Lancet. Diabetes & Endocrinology|January 12, 2020
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trialHertzel C Gerstein, Robert Hart, Helen M Colhoun, et al.
Diabetologia|September 26, 2013
HbA1c, fasting and 2 h plasma glucose in current, ex- and never-smokers: a meta-analysisSoraya Soulimane, Dominique Simon, William H Herman, et al.
The Lancet. Diabetes & Endocrinology|November 9, 2025
Time trends in mortality from heart failure and atherosclerotic cardiovascular disease in people with and without diabetes: a multi-national population-based studyJoanna Y Gong, Jedidiah I Morton, Lei Chen, et al.
The Lancet. Diabetes & Endocrinology|March 12, 2026
Trends in cause-specific mortality among people with and without diabetes in high-income settings: a multinational, population-based studyDianna J Magliano, Jedidiah I Morton, Lei Chen, et al.
Pageof 41

Showing results (381-390 of 407) with videos related to

Sort By:
Pageof 41
Journal of Lipid Research|April 11, 2025
Statin effects on the lipidome: Predicting statin usage and implications for cardiovascular risk predictionChangyu Yi, Kevin Huynh, Yvette Schooneveldt, et al.
BMJ Open Diabetes Research & Care|January 8, 2020
Comparing different definitions of prediabetes with subsequent risk of diabetes: an individual participant data meta-analysis involving 76 513 individuals and 8208 cases of incident diabetesCrystal Man Ying Lee, Stephen Colagiuri, Mark Woodward, et al.
Cardiovascular Diabetology|November 26, 2020
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysisGilles R Dagenais, Lars Rydén, Lawrence A Leiter, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2022
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND TrialTali Cukierman-Yaffe, Hertzel C Gerstein, Jan Basile, et al.
The Lancet. Diabetes & Endocrinology|March 31, 2015
A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveysKaveh Hajifathalian, Peter Ueda, Yuan Lu, et al.
The Lancet. Neurology|June 21, 2020
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialTali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, et al.
The Lancet. Diabetes & Endocrinology|January 12, 2020
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trialHertzel C Gerstein, Robert Hart, Helen M Colhoun, et al.
Diabetologia|September 26, 2013
HbA1c, fasting and 2 h plasma glucose in current, ex- and never-smokers: a meta-analysisSoraya Soulimane, Dominique Simon, William H Herman, et al.
The Lancet. Diabetes & Endocrinology|November 9, 2025
Time trends in mortality from heart failure and atherosclerotic cardiovascular disease in people with and without diabetes: a multi-national population-based studyJoanna Y Gong, Jedidiah I Morton, Lei Chen, et al.
The Lancet. Diabetes & Endocrinology|March 12, 2026
Trends in cause-specific mortality among people with and without diabetes in high-income settings: a multinational, population-based studyDianna J Magliano, Jedidiah I Morton, Lei Chen, et al.
Pageof 41